Why NeoGenomics (NEO) Shares Are Falling Today
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in the following investor conferences:...
NEO Q4 Deep Dive: Product Mix Shift and Guidance Weigh on Outlook
NeoGenomics’s (NASDAQ:NEO) Q4 CY2025 Sales Beat Estimates
Full-year revenue increased 10% to $727 million; Full-year clinical revenue grew 15%, or 13% excluding the Pathline acquisition; Successfully resolved RaDaR ST patent...
NeoGenomics (NEO) Q4 Earnings Report Preview: What To Look For
New integrated testing approach provides potential to deliver earlier biomarker insights, reduce diagnostic uncertainty in complex cancer cases, and enable confident clinical decisions
1 Stock Under $50 Worth Your Attention and 2 We Brush Off
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its fourth quarter and full year 2025 financial...